BeiGene: Dr. Olivier Brandicourt appointed as an independent non-executive director of the board of directors
宋哥TY
发表于 2024-1-23 20:04:42
1368
0
0
Baekje Shenzhou (SH 688235, closing price: 122.8 yuan) announced on the evening of January 23 that Mr. Thomas Malley resigned from his position as an independent non-executive director and corresponding position on a special committee of the board of directors of Baekje Shenzhou Co., Ltd. on January 22, 2024, due to plans to devote more time to other affairs. After deliberation by the company's board of directors, Dr. Olivier Brandicourt has been appointed as an independent non-executive director of the board of directors.
As of publication, the market value of BeiGene is 166.4 billion yuan.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process
- BeiGene executive Yin Min is under investigation after previously serving at AstraZeneca | News
- A senior executive of BeiGene has been investigated, and insiders say that the reason for the investigation is unrelated to BeiGene
- BeiGene executive Yin Min is suspected of smuggling and cooperating with the investigation
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
- Arm's CEO will serve as a non-executive director of AstraZeneca
- BeiGene: NASDAQ stock code will be changed to 'ONC'
- BeiGene NASDAQ stock code will be changed to 'ONC'
- BeiGene issues 100000 shares, with an increase of 0.007%
- BeiGene and BeiZeAn are approved for new indications in the United States